No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Fermenta Biotech Ltd. primarily focuses on the creation and provision of Vitamin D3. Their extensive range of offerings includes various forms like crystalline, oil, resin in oil, cold water dispersible (CWD) preparations, and feed-grade powder. These adaptable products are utilized across multiple sectors, such as in pharmaceutical injectables, soft gel capsules, premixes, and for enhancing the nutritional value of food and beverages. The company's business activities are structured into two main divisions: the Chemicals/Bulk Drug segment, which involves the production and sale of chemicals, pharmaceutical ingredients, and enzymes; and the Property segment, dedicated to leasing out real estate. Established on May 1, 1951, by Vijay Kumar Raju Datla, the firm maintains its headquarters in Mumbai, India.
www.fermentabiotech.comNo one on the platform currently holds FERMENTA.BO.
No tracked institution reports a position in FERMENTA.BO as of their last filing.
No one on the platform has traded FERMENTA.BO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 11.6% | — | — | — | ||
| Rev. Growth % | 11.6% | 7.1% | ||||
| Profit Margin % | 13.7% | 2.5% | 8.0% | |||
| Free Cash Flow Margin % | 10.6% | 12.7% | 5.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $2.9B | -44.3% | $20.20 | $20.20–$20.20 | — | 1 |
| 2028 | $3.8B | +28.8% | $15.50 | $15.50–$15.50 | — | 1 |
| 2029 | $4.5B | +19.9% | $16.80 | $16.80–$16.80 | — | 1 |
| 2030 | $5.3B | +16.3% | $23.20 | $23.20–$23.20 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-11 | $3.30 | $3.40 | +3.0% |
| 2026-05-26 | $3.30 | $6.37 | +93.0% |
| 2026-02-09 | $3.80 | $4.36 | +14.7% |
| 2025-11-12 | $2.50 | $6.48 | +159.2% |
| 2025-08-12 | $3.30 | $7.49 | +127.0% |
| 2025-05-28 | $3.30 | $11.84 | +258.8% |
| 2025-02-11 | $2.50 | $12.71 | +408.4% |
| 2024-11-14 | $3.30 |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| FERMENTA.BOFermenta Biotech Ltd. | $468.85 | -0.50% | $13.4B | — |
| ANUHPHR.BOAnuh Pharma Limited | $89.42 | -0.81% | $9.0B | — |
| BPLPHARMA.BOBharat Parenterals Limited | $1517.05 | -2.13% | $10.5B | — |
| KOPRAN.BOKopran Limited | $260.60 | +4.39% | $12.6B | — |
| KOPRAN.NSKopran Limited |
| $3.94 |
| +19.4% |
| $260.86 |
| +4.39% |
| $12.6B |
| — |
| KPL.BOKwality Pharmaceuticals Limited | $3348.05 | -2.81% | $34.7B | — |
| PRAVEG.BOPraveg Ltd. | $253.15 | -0.88% | $6.6B | — |
Source: Financial Modeling Prep · peers by sector/industry